Key result
Korean schoolchildren exhibit ~82% seropositivity for all three poliovirus types, with lowest type III immunity.
Why the study?
The seroprevalence of poliovirus antibody among primary schoolchildren in Korea was not well characterized, particularly for type III poliovirus.
What is the seroprevalence of poliovirus antibodies among primary schoolchildren in Korea?
Cross-Sectional (n=500)
Yes
What is the seroprevalence of poliovirus antibodies among primary schoolchildren in Korea?
The study demonstrates high seroprevalence for poliovirus types I and II but lower rates for type III among Korean schoolchildren, suggesting the type III component of the oral polio vaccine may need further evaluation.
Warrants vigilance for type III polio susceptibility in Korean schoolchildren; leaves open whether vaccination strategies require modification.
We aimed to determine the seroprevalence of poliovirus antibody in Korea by using the cell culture neutralization method recommended by the WHO. A total of 500 sera collected from children at eight primary schools in Kyunggi province were used for this study. We found that 82.2% of children were positive for all three types of poliovirus and antibody-positive rates for types I, II and III were 94.4, 96.6 and 86.8% respectively, indicating that seropositive rates for types I and II were considerably higher than for type III (P<0.0001). This result implies that the type III component of the oral polio vaccine should be evaluated further. Although a greater number of children, including young infants, need to be tested for seroprevalence, this study still provides us with valuable information on the effectiveness of vaccination against polioviruses in Korea.
No takes yet. Share an insight, caveat, or question.
Jee et al. (2004) conducted a cross-sectional in Poliovirus immunity (n=500). Poliovirus vaccination was evaluated on Seropositivity for all three types of poliovirus. Among primary schoolchildren in Korea, 82.2% were seropositive for all three types of poliovirus, with significantly lower immunity to type III (86.8%) compared to types I and II (P<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: